

Funnel plot of comparison: 1 IIEF-EF change scores: blinding across 4 RoB domains, outcome: 1.2 Effect estimate intervention groups.

Figure 4 (Analysis 6.1)

				Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
SIL001	2.3	0.67989	2.0%	2.30 [0.97, 3.63]	-
SIL002	5.2	0.663129	2.0%	5.20 [3.90, 6.50]	_
SIL003	3.6	0.714299	1.9%	3.60 [2.20, 5.00]	_
SIL006	6.38	0.966705	1.5%	6.38 [4.49, 8.27]	
SIL007	0.3	1.753625	0.8%	0.30 [-3.14, 3.74]	
SIL011	3.4	1.000253	1.5%	3.40 [1.44, 5.36]	
SIL014		0.961774	1.5%	1.86 [-0.03, 3.75]	-
SIL016	2.2	0.899509	1.6%	2.20 [0.44, 3.96]	
SIL017	1.4	0.599619	2.1%	1.40 [0.22, 2.58]	-
SIL018	0.2		2.1%	0.20 [-0.98, 1.38]	+
SIL022	2.1	0.418374	2.4%	2.10 [1.28, 2.92]	-
SIL023	2.2		2.5%	2.20 [1.45, 2.95]	-
SIL024		1.080105	1.4%	2.60 [0.48, 4.72]	
SIL025	1.4	1.000253	1.5%	1.40 [-0.56, 3.36]	<u> </u>
SIL026		0.699906	2.0%	-0.50 [-1.87, 0.87]	-
SIL027	0.92		0.6%	0.92 [-3.15, 4.99]	
SIL028		1.247726	1.2%	1.24 [-1.21, 3.69]	T
SIL030		0.699719	2.0%	1.10 [-0.27, 2.47]	<u> </u>
SIL034	2.66	1.069968	1.4%	2.66 [0.56, 4.76]	
SIL15	-1.2	2.18 0.727055	0.5%	0.00 [-4.27, 4.27]	
SIL16	2.3		1.9%	-1.20 [-2.63, 0.23]	
SIL25 SIL35		0.772015 0.730352	1.8%	2.30 [0.79, 3.81]	
SIL36	1.1		2.1%	4.56 [3.13, 5.99]	
SIL40	1.38	0.012132	1.9%	1.10 [-0.10, 2.30] 1.38 [-0.07, 2.83]	
SIL40		0.683699	2.0%		
SIL410	1.7	1.270435	1.2%	2.90 [1.56, 4.24] 1.70 [-0.79, 4.19]	
SIL51	4.5	0.781353	1.8%	4.50 [2.97, 6.03]	
SIL53	2.5	1.549244	0.9%	2.50 [-0.54, 5.54]	
TAD005	0.87		1.8%	0.87 [-0.64, 2.38]	
TAD005	2.3	1.60068	0.9%	2.30 [-0.84, 5.44]	
TAD000		0.612152	2.1%	1.30 [0.10, 2.50]	
TAD01		1.099852	1.4%	-0.90 [-3.06, 1.26]	
TAD012		0.781353	1.8%	0.49 [-1.04, 2.02]	_
TAD015	3.3		1.9%	3.30 [1.87, 4.73]	
TAD018	1.8	0.51001	2.3%	1.80 [0.80, 2.80]	-
TAD03		0.783276	1.8%	0.10 [-1.44, 1.64]	+
TAD06	0.7	0.719907	1.9%	0.70 [-0.71, 2.11]	+
TAD07	-0.2	1.08075	1.4%	-0.20 [-2.32, 1.92]	+
TAD08	0.3	0.79963	1.8%	0.30 [-1.27, 1.87]	+
TAD09	0.4	0.942857	1.6%	0.40 [-1.45, 2.25]	+
TAD10	1.4	0.689143	2.0%	1.40 [0.05, 2.75]	
TAD16	1.1	0.6153	2.1%	1.10 [-0.11, 2.31]	
TAD18	1	0.899244	1.6%	1.00 [-0.76, 2.76]	+
VAR001	2.3	0.7475	1.9%	2.30 [0.83, 3.77]	
VAR003	2.6	0.676015	2.0%	2.60 [1.28, 3.92]	-
VAR006	2.05	0.474335	2.4%	2.05 [1.12, 2.98]	_
VAR007	1.6		1.5%	1.60 [-0.35, 3.55]	
VAR015	3.63	4.850045		3.63 [-5.88, 13.14]	-
VAR018	1.4	0.52307	2.3%	1.40 [0.37, 2.43]	-
VAR019	1.4	0.48541	2.3%	1.40 [0.45, 2.35]	
VAR02		0.594552	2.1%	1.20 [0.03, 2.37]	_
VAR020		0.966705	1.5%	0.48 [-1.41, 2.37]	+
VAR04	3.1		1.8%	3.10 [1.56, 4.64]	—
VAR05	1.5	0.469631	2.4%	1.50 [0.58, 2.42]	-
VAR11	0.5	0.403791	2.5%	0.50 [-0.29, 1.29]	<u>†</u>
VAR12	1.3	0.432945	2.4%	1.30 [0.45, 2.15]	_
Total (05% CI)			100.00	1 71 (1 20 2 20)	
Total (95% CI)	1 12 662	01 16	100.0%	1.71 [1.36, 2.05]	
Heterogeneity: Tau ² =			(P < 0.00)	J001); I* = 70%	-10 -5 0 5 10
Test for overall effect	. Z = 9.57 (P < 0.00	JUU1)			Favours no effect Favours effect

Forest plot of comparison: 6 IIEF-EF change scores: RCTs using parallel and crossover design, outcome: 6.1 Effect estimate placebo groups.

Figure 5 (Analysis 6.2)

Study on Sub-	M D:ff		W-!	Mean Difference	Mean Di	
Study or Subgroup	Mean Difference		Weight	IV, Random, 95% CI	IV, Rando	m, 95% CI
SIL001		0.679833	1.9%	9.10 [7.77, 10.43]		
SIL002	11.7		1.9%	11.70 [10.40, 13.00]		
SIL003		0.714353	1.9%	9.30 [7.90, 10.70]		
SIL006		1.358089	1.5%	11.08 [8.42, 13.74]		
SIL007		1.753625	1.2%	9.30 [5.86, 12.74]		
SIL011	8.9	1.000203	1.7%	8.90 [6.94, 10.86]		
SIL014	9.17	0.979662	1.7%	9.17 [7.25, 11.09]		
SIL016	8	0.899606	1.8%	8.00 [6.24, 9.76]		
SIL017	8.7	0.599619	1.9%	8.70 [7.52, 9.88]		
SIL018	6.1	0.600082	1.9%	6.10 [4.92, 7.28]		-
SIL022	9.5	0.316981	2.1%	9.50 [8.88, 10.12]		-
SIL023	3.6	0.390199	2.0%	3.60 [2.84, 4.36]		-
SIL024	7.2	0.750467	1.9%	7.20 [5.73, 8.67]		
SIL025	6.8	1.20049	1.6%	6.80 [4.45, 9.15]		
SIL026		0.599959	1.9%	2.10 [0.92, 3.28]		
SIL027	5.79	1.54477	1.3%	5.79 [2.76, 8.82]		
SILO28		1.187939	1.6%	6.39 [4.06, 8.72]		
SIL030		0.599587	1.9%	5.40 [4.22, 6.58]		
SIL030		0.920249	1.7%	10.37 [8.57, 12.17]		
		1.158283	1.6%			
SIL15				7.00 [4.73, 9.27]		
SIL16		0.714353	1.9%	8.40 [7.00, 9.80]		
SIL25		0.743194		12.30 [10.84, 13.76]		
SIL35		0.720818	1.9%	10.66 [9.25, 12.07]		
SIL36		0.716198	1.9%	10.00 [8.60, 11.40]		
SIL40	5.98	0.73978	1.9%	5.98 [4.53, 7.43]		
SIL41b		0.713379	1.9%	9.70 [8.30, 11.10]		
SIL44	13.3		0.7%	13.30 [7.89, 18.71]		→
SIL5 1	9.5	0.837855	1.8%	9.50 [7.86, 11.14]		
SIL53	11.2	1.462624	1.4%	11.20 [8.33, 14.07]		
TAD005	9.35	0.804142	1.8%	9.35 [7.77, 10.93]		-
TAD006	9.3	0.800167	1.8%	9.30 [7.73, 10.87]		
TAD009	4.5	0.71988	1.9%	4.50 [3.09, 5.91]		-
TAD01	8	0.79949	1.8%	8.00 [6.43, 9.57]		
TAD012	8.03	0.448769	2.0%	8.03 [7.15, 8.91]		-
TAD015	7.3		2.0%	7.30 [6.33, 8.27]		-
TAD018	6.5	0.4899	2.0%	6.50 [5.54, 7.46]		-
TAD03		1.096016	1.6%	7.30 [5.15, 9.45]		
TAD06		1.012517	1.7%	5.60 [3.62, 7.58]		
TAD07		0.750126	1.9%	6.90 [5.43, 8.37]		
TAD07		0.600161	1.9%	9.30 [8.12, 10.48]		
TADOS		2.111129	1.0%	11.10 [6.96, 15.24]		
TAD10	9.8		2.0%	9.80 [9.00, 10.60]		
						_
TAD16	5.3		2.0%	5.30 [4.31, 6.29]		
TAD18	7.8	1.2	1.6%	7.80 [5.45, 10.15]		
VAR001		0.436011	2.0%	8.80 [7.95, 9.65]		_
VAR003		0.386822	2.0%	9.00 [8.24, 9.76]		_
VAR006		0.634635	1.9%	7.79 [6.55, 9.03]		
VAR007		0.819436	1.8%	10.90 [9.29, 12.51]		
VAR015		4.589402	0.3%	4.56 [-4.44, 13.56]		-
VAR018		0.547024	2.0%	8.60 [7.53, 9.67]		
VAR019		0.627571	1.9%	8.50 [7.27, 9.73]		_
VAR02		0.562143	2.0%	9.00 [7.90, 10.10]		_
VAR020	8.95	1.390048	1.4%	8.95 [6.23, 11.67]		
VAR04	12.6	1.144751	1.6%	12.60 [10.36, 14.84]		
VAR05	10.8	0.636719	1.9%	10.80 [9.55, 12.05]		-
VAR11	8.2	0.50824	2.0%	8.20 [7.20, 9.20]		
VAR12		0.463406	2.0%	8.80 [7.89, 9.71]		-
Total (95% CI)			100.0%	8.36 [7.78, 8.94]		•
Heterogeneity: Tau2 =	4.13; Chi ² = 582.	42, df = 56	(P < 0.00		12 -	<u> </u>
Test for overall effect:						5 10
		,			Favours no effect	ravours effect

Forest plot of comparison: 6 IIEF-EF change scores: RCTs using parallel and crossover design, outcome: 6.2 Effect estimate intervention groups.

Figure 6 (Analysis 7.1)

				Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
SIL001	2.3	0.67989	2.1%	2.30 [0.97, 3.63]	-
SIL002	5.2	0.663129	2.1%	5.20 [3.90, 6.50]	-
SIL003	3.6	0.714299	2.0%	3.60 [2.20, 5.00]	
SIL011	3.4	1.000253	1.5%	3.40 [1.44, 5.36]	
SIL014	1.86	0.961774	1.6%	1.86 [-0.03, 3.75]	
SIL016	2.2	0.899509	1.7%	2.20 [0.44, 3.96]	
SIL017	1.4	0.599619	2.3%	1.40 [0.22, 2.58]	-
SIL018	0.2	0.599656	2.3%	0.20 [-0.98, 1.38]	+
SIL022	2.1	0.418374	2.6%	2.10 [1.28, 2.92]	-
SIL023	2.2	0.381528	2.7%	2.20 [1.45, 2.95]	-
SIL024		1.080105	1.4%	2.60 [0.48, 4.72]	
SIL025		1.000253	1.5%	1.40 [-0.56, 3.36]	
SIL026		0.699906	2.1%	-0.50 [-1.87, 0.87]	+
SIL027		2.077352	0.6%	0.92 [-3.15, 4.99]	
SIL030		0.699719	2.1%	1.10 [-0.27, 2.47]	
SIL034		1.069968	1.4%	2.66 [0.56, 4.76]	
SIL15	0	2.18	0.5%	0.00 [-4.27, 4.27]	
SIL16		0.727055	2.0%	-1.20 [-2.63, 0.23]	_
SIL25		0.772015	1.9%	2.30 [0.79, 3.81]	
SIL35		0.730352	2.0%	4.56 [3.13, 5.99]	_
SIL36		0.612152	2.3%	1.10 [-0.10, 2.30]	_
SIL40		0.741728	2.0%	1.38 [-0.07, 2.83]	_
SIL41b		0.683699	2.1%	2.90 [1.56, 4.24]	-
SIL44		1.270435	1.2%	1.70 [-0.79, 4.19]	
SIL51		0.781353	1.9%	4.50 [2.97, 6.03]	-
SIL53		1.549244	0.9%	2.50 [-0.54, 5.54]	
TADOOS		0.771589	1.9%	0.87 [-0.64, 2.38]	<u> </u>
TADOO6	2.3	1.60068	0.9%	2.30 [-0.84, 5.44]	
TAD009		0.612152	2.3%	1.30 [0.10, 2.50]	
TAD012		1.099852		-0.90 [-3.06, 1.26]	I
TAD012 TAD015		0.781353	1.9% 2.0%	0.49 [-1.04, 2.02] 3.30 [1.87, 4.73]	T
TAD013	1.8	0.51001	2.5%	1.80 [0.80, 2.80]	
TAD018		0.783276	1.9%	0.10 [-1.44, 1.64]	<u> </u>
TAD03		0.719907	2.0%	0.70 [-0.71, 2.11]	_
TAD00	-0.2	1.08075		-0.20 [-2.32, 1.92]	
TAD07	0.3	0.79963	1.9%	0.30 [-1.27, 1.87]	_
TAD09		0.942857	1.6%	0.40 [-1.45, 2.25]	
TAD10		0.689143	2.1%	1.40 [0.05, 2.75]	
TAD16	1.1	0.6153	2.2%	1.10 [-0.11, 2.31]	
TAD18		0.899244	1.7%	1.00 [-0.76, 2.76]	
VAR001	2.3	0.7475	2.0%	2.30 [0.83, 3.77]	
VAR003		0.676015	2.1%	2.60 [1.28, 3.92]	
VAR006		0.474335	2.5%	2.05 [1.12, 2.98]	-
VAR007	1.6	0.994066	1.5%	1.60 [-0.35, 3.55]	 -
VAR015		4.850045		3.63 [-5.88, 13.14]	
VAR018	1.4	0.52307	2.4%	1.40 [0.37, 2.43]	-
VAR019	1.4	0.48541	2.5%	1.40 [0.45, 2.35]	-
VAR02	1.2	0.594552	2.3%	1.20 [0.03, 2.37]	
VAR04		0.783276	1.9%	3.10 [1.56, 4.64]	-
VAR05	1.5	0.469631	2.5%	1.50 [0.58, 2.42]	-
VAR11	0.5	0.403791	2.7%	0.50 [-0.29, 1.29]	+
VAR12	1.3	0.432945	2.6%	1.30 [0.45, 2.15]	_
Total (95% CI)			100.0%	1.67 [1.33, 2.01]	•
Heterogeneity: Tau ² =			(P < 0.00)	$(0001); I^2 = 67\%$	-10 -5 0 5 10
Test for overall effect:	Z = 9.61 (P < 0.00	0001)			Favours no effect Favours effect

Forest plot of comparison: 7 IIEF-EF change scores: RCTs using parallel design, outcome: 7.1 Effect estimate placebo groups.

Figure 7 (Analysis 7.2)

				Mean Difference	Mean Di	fference
Study or Subgroup	Mean Difference	SE	Weight	IV, Random, 95% CI	IV, Rando	m, 95% CI
SIL001	9.1	0.679833	2.0%	9.10 [7.77, 10.43]		+
SIL002	11.7	0.663333	2.0%	11.70 [10.40, 13.00]		-
SIL003		0.714353	2.0%	9.30 [7.90, 10.70]		
SIL011	8.9	1.000203	1.8%	8.90 [6.94, 10.86]		
SIL014	9.17	0.979662	1.8%	9.17 [7.25, 11.09]		
SIL016	8	0.899606	1.9%	8.00 [6.24, 9.76]		
SIL017	8.7	0.599619	2.1%	8.70 [7.52, 9.88]		-
SIL018	6.1	0.600082	2.1%	6.10 [4.92, 7.28]		-
SIL022	9.5	0.316981	2.2%	9.50 [8.88, 10.12]		-
SIL023	3.6	0.390199	2.2%	3.60 [2.84, 4.36]		-
SIL024	7.2		2.0%	7.20 [5.73, 8.67]		
SIL025	6.8	1.20049	1.7%	6.80 [4.45, 9.15]		
SIL026		0.599959	2.1%	2.10 [0.92, 3.28]		-
SIL027	5.79	1.54477	1.4%	5.79 [2.76, 8.82]		
SIL030		0.599587	2.1%	5.40 [4.22, 6.58]		-
SIL034		0.920249	1.9%	10.37 [8.57, 12.17]		
SIL15		1.158283	1.7%	7.00 [4.73, 9.27]		
SIL16		0.714353	2.0%	8.40 [7.00, 9.80]		
SIL25		0.743194	2.0%	12.30 [10.84, 13.76]		
SIL35		0.720818	2.0%	10.66 [9.25, 12.07]		
SIL36		0.716198	2.0%	10.00 [8.60, 11.40]		
SIL40	5.98	0.73978	2.0%	5.98 [4.53, 7.43]		
SIL41b		0.713379	2.0%	9.70 [8.30, 11.10]		
SIL44		2.760809	0.8%	13.30 [7.89, 18.71]		
SIL51		0.837855	1.9%	9.50 [7.86, 11.14]		
SIL53		1.462624	1.5%	11.20 [8.33, 14.07]		
TAD005		0.804142	1.9%	9.35 [7.77, 10.93]		
TAD006	9.3		1.9%	9.30 [7.73, 10.87]		
TAD009	4.5	0.71988	2.0%	4.50 [3.09, 5.91]		
TAD01	8	0.79949	1.9%	8.00 [6.43, 9.57]		
TAD012		0.448769	2.1%	8.03 [7.15, 8.91]		_
TAD015	7.3		2.1%	7.30 [6.33, 8.27]		_
TAD018	6.5	0.4899	2.1%	6.50 [5.54, 7.46]		
TADOS		1.096016	1.7%	7.30 [5.15, 9.45]		
TAD06 TAD07		1.012517	1.8%	5.60 [3.62, 7.58]		
		0.750126	2.0%	6.90 [5.43, 8.37]		
TAD08 TAD09		0.600161 2.111129	2.1% 1.1%	9.30 [8.12, 10.48]		
TAD10		0.408084	2.1%	11.10 [6.96, 15.24]		
TAD10	5.3		2.1%	9.80 [9.00, 10.60] 5.30 [4.31, 6.29]		_
TAD16	7.8	1.2	1.7%	7.80 [5.45, 10.15]		
VAR001		0.436011	2.1%	8.80 [7.95, 9.65]		_
VAROU1 VAROU3		0.386822	2.2%	9.00 [8.24, 9.76]		-
VAROOS VAROO6		0.634635	2.0%	7.79 [6.55, 9.03]		
VAR000 VAR007		0.819436	1.9%	10.90 [9.29, 12.51]		
VAR015		4.589402	0.4%	4.56 [-4.44, 13.56]		
VAR018		0.547024	2.1%	8.60 [7.53, 9.67]		-
VAR019		0.627571	2.0%	8.50 [7.27, 9.73]		
VAR013 VAR02		0.562143	2.1%	9.00 [7.90, 10.10]		
VAR04		1.144751	1.7%			
VAR05		0.636719	2.0%	10.80 [9.55, 12.05]		
VAR11	8.2	0.50824	2.1%	8.20 [7.20, 9.20]		
VAR12		0.463406	2.1%	8.80 [7.89, 9.71]		
	3.0	35		(1.00, 5.71)		
Total (95% CI)			100.0%	8.33 [7.73, 8.93]		•
Heterogeneity: Tau2 =	4.17; Chi ² = 574.	81, df = 52				· ·
Test for overall effect						5 10
					Favours no effect	ravours effect

Forest plot of comparison: 7 IIEF-EF change scores: RCTs using parallel design, outcome: 7.2 Effect estimate intervention groups.

Figure 8 (Analysis 8.1)

				Mean Difference	Mean Di	fference
Study or Subgroup	Mean Difference	SE	Weight	IV, Random, 95% CI	IV, Rando	m, 95% CI
SIL006	6.38	0.966705	17.0%	6.38 [4.49, 8.27]		
SIL007	0.3	1.753625	11.9%	0.30 [-3.14, 3.74]		
SIL028	1.24	1.247726	15.1%	1.24 [-1.21, 3.69]	_	•
SIL1b	0.8	5.641379	2.4%	0.80 [-10.26, 11.86]		
SIL2 a	0.9	4.246676	3.8%	0.90 [-7.42, 9.22]		-
SIL2f	5.3	1.494917	13.5%	5.30 [2.37, 8.23]		
VAR017	3	0.59794	19.3%	3.00 [1.83, 4.17]		-
VAR020	0.48	0.966705	17.0%	0.48 [-1.41, 2.37]	-	-
Total (95% CI)			100.0%	2.74 [0.94, 4.54]		•
Heterogeneity: Tau2 =	4.02; Chi ² = 26.1	3, df = 7 (P)	= 0.0005	$(5); I^2 = 73\%$	10 -	5 10
Test for overall effect:	Z = 2.98 (P = 0.00)	03)			favours no effect	


Forest plot of comparison: 8 IIEF-EF change scores: RCTs using crossover design, outcome: 8.1 Effect estimate placebo groups.

Figure 9 (Analysis 8.2)

				Mean Difference	Mean Di	fference
Study or Subgroup	Mean Difference	SE	Weight	IV, Random, 95% CI	IV, Rando	m, 95% CI
SIL006	11.08	1.358089	15.8%	11.08 [8.42, 13.74]		
SIL007	9.3	1.753625	11.5%	9.30 [5.86, 12.74]		
SIL028	6.39	1.187939	18.2%	6.39 [4.06, 8.72]		
SIL1b	6	5.1878	1.8%	6.00 [-4.17, 16.17]	_	
SIL2 a	7.2	4.0184	3.0%	7.20 [-0.68, 15.08]	-	•
SIL2f	13.3	2.87	5.4%	13.30 [7.67, 18.93]		
VAR017	10.1	0.5949	28.8%	10.10 [8.93, 11.27]		-
VAR020	8.95	1.390048	15.4%	8.95 [6.23, 11.67]		-
Total (95% CI)			100.0%	9.32 [7.90, 10.74]		•
Heterogeneity: Tau ² =			= 0.10);	$I^2 = 41\%$	-10 -5	5 10
Test for overall effect:	Z = 12.87 (P < 0.0)	00001)			favours no effect	favours effect

Forest plot of comparison: 8 IIEF-EF change scores: RCTs using crossover design, outcome: 8.2 Effect estimate intervention groups.

Figure 10 (Analysis 9.1)




Forest plot of comparison: 9 IIEF-EF change scores: Commercial Funding, outcome: 9.1 Effect estimate placebo groups.

Figure 11 (Analysis 9.2)

				Mean Difference	Mean Difference
Study or Subgroup	Mean Difference		Weight	IV, Random, 95% CI	IV, Random, 95% CI
9.2.1 Not commercia	ıl (Public / Mixed fı	ınding)		
SIL027	5.79	1.54	2.1%	5.79 [2.77, 8.81]	
SIL15	7	1.91	1.7%	7.00 [3.26, 10.74]	
SIL1b	6	2.43	1.3%	6.00 [1.24, 10.76]	
SIL2f	13.3	2.87	1.1%	13.30 [7.67, 18.93]	
SIL44		2.76	1.1%	13.30 [7.89, 18.71]	
Subtotal (95% CI)			7.3%	8.56 [5.47, 11.64]	•
Heterogeneity: Tau2 =	7.25: Chi ² = 10.0	7. df =	4(P = 0)	$.04$); $I^2 = 60\%$	
Test for overall effect:					
	, , , , , , , , , , , , , , , , , , , ,				
9.2.3 Commercial					
SIL001	9.1	0.68	3.0%	9.10 [7.77, 10.43]	_
SIL002	11.7	0.66	3.1%	11.70 [10.41, 12.99]	-
SIL011	8.9	1	2.7%	8.90 [6.94, 10.86]	
SIL014	9.17	0.98	2.7%	9.17 [7.25, 11.09]	
SIL016	8	0.9	2.8%	8.00 [6.24, 9.76]	
SIL017	8.7	0.6	3.1%	8.70 [7.52, 9.88]	_
SIL018	6.1	0.6	3.1%	6.10 [4.92, 7.28]	_
SIL022	9.5	0.32	3.3%	9.50 [8.87, 10.13]	+
SIL025	6.8	1.2	2.5%	6.80 [4.45, 9.15]	
SIL026	2.1	0.6	3.1%	2.10 [0.92, 3.28]	-
SIL030	5.4	0.6	3.1%	5.40 [4.22, 6.58]	_
SIL034	10.37		2.8%	10.37 [8.57, 12.17]	
TAD005	9.35	0.8	2.9%	9.35 [7.78, 10.92]	
TAD005	9.3	0.8	2.9%	9.30 [7.73, 10.87]	
TAD000	8	0.8	2.9%	8.00 [6.43, 9.57]	
TAD01		0.45	3.2%	8.03 [7.15, 8.91]	_
TAD012	7.3	0.43	3.2%	7.30 [6.32, 8.28]	_
TAD013		0.49	3.2%	6.50 [5.54, 7.46]	_
TAD018	7.3	1.1	2.6%	7.30 [5.14, 9.46]	
TAD03		0.75	3.0%	6.90 [5.43, 8.37]	
TAD07	9.3	0.73	3.1%	9.30 [8.12, 10.48]	
TAD08		0.56		11.10 [10.00, 12.20]	_
TAD10		0.41	3.3%	9.80 [9.00, 10.60]	
TAD10		0.51	3.2%	5.30 [4.30, 6.30]	
TAD16	7.8	1.2	2.5%	7.80 [5.45, 10.15]	
VAR006		0.63	3.1%	7.79 [6.56, 9.02]	
		0.82	2.9%		
VAROUT				10.90 [9.29, 12.51]	
VAR015		0.96	2.7%	4.56 [2.68, 6.44]	- .
VAR018		0.55	3.2%	8.60 [7.52, 9.68]	
VAR019		0.63	3.1%	8.50 [7.27, 9.73]	-
VAR11 Subtotal (95% CI)	8.2	0.51	3.2% 92.7 %	8.20 [7.20, 9.20]	
	2 71 612 220			8.08 [7.35, 8.80]	▼
Heterogeneity: Tau ² =				$(0.00001); \Gamma = 91\%$	
Test for overall effect:	Z = 21.84 (P < 0.0)	00001)			
Total (05% CI)			100.0%	9 10 17 40 9 901	
Total (95% CI)	2 72 612 222		100.0%	8.10 [7.40, 8.80]	l . ₹.
Heterogeneity: Tau ² =				$(0.00001); \Gamma = 89\%$	-10 -5 0 5 10
Test for overall effect:				77) 12 00/	Favours no effect Favours effect
Test for subgroup diff	ierences: Cni = 0.0	9, at =	: I (b = 0	7.77), F = 0%	

Forest plot of comparison: 9 IIEF-EF change scores: Commercial Funding, outcome: 9.2 Effect estimate intervention groups.

Figure 12 (Analysis 10.1)



Forest plot of comparison: 10 IIEF-EF change scores: Continent, outcome: 10.1 Effect estimate placebo groups.

Figure 13 (Analysis 10.2)

Study or Subgroup	Mean Difference	SE	Weight	Mean Difference IV, Random, 95% CI		fference m, 95% CI
10.2.1 Across contin	ents					
SIL001	9.1	0.67983266	2.3%	9.10 [7.77, 10.43]		
SIL002	11.7	0.66333333	2.3%	11.70 [10.40, 13.00]		
SIL017	8.7	0.59961949	2.3%	8.70 [7.52, 9.88]		-
SIL022		0.31698117	2.4%	9.50 [8.88, 10.12]		-
SIL48		0.95863335	2.1%	7.00 [5.12, 8.88]		
TAD005		0.80414166	2.2%	9.35 [7.77, 10.93]		
TAD006		0.80016665	2.2%	9.30 [7.73, 10.87]		
TAD000		0.71988043	2.2%			
				4.50 [3.09, 5.91]		
TAD012		0.44876926	2.4%	8.03 [7.15, 8.91]		_
TAD018		0.48989996	2.4%	6.50 [5.54, 7.46]		_
TAD06		1.03344151	2.0%	5.60 [3.57, 7.63]		
TAD10		0.40808442	2.4%	9.80 [9.00, 10.60]		_
TAD16		0.50642857	2.4%	5.30 [4.31, 6.29]		
VAR004		0.51042815	2.4%	9.50 [8.50, 10.50]		_
VAR005	10	0.39467611	2.4%	10.00 [9.23, 10.77]		-
VAR018	8.6	0.54702374	2.3%	8.60 [7.53, 9.67]		-
VAR019	8.5	0.62757064	2.3%	8.50 [7.27, 9.73]		
VAR05	10.8	0.63671908	2.3%	10.80 [9.55, 12.05]		-
VAR07	8.3	0.46226179	2.4%	8.30 [7.39, 9.21]		-
Subtotal (95% CI)			43.5%	8.47 [7.70, 9.24]		•
Heterogeneity: Tau2 =	2.53: Chi ² = 174.	37. df = 18 (P	< 0.0000			
Test for overall effect: 10.2.2 Africa				,,		
SII 47	11.5	0.67340033	3 307	11 20 (0 00 12 52)		
	11.2	0.67349833	2.3% 2.3%	11.20 [9.88, 12.52] 11.20 [9.88, 12.52]		
Subtotal (95% CI)	nlienhle		2.3%	11.20 [3.00, 12.32]		•
Heterogeneity: Not ap Test for overall effect:		00001)				
10.2.3 Asia						
SIL006	11.08	1.49240501	1.7%	11.08 [8.15, 14.01]		
SIL007	9.3	1.75362482	1.5%	9.30 [5.86, 12.74]		
SIL009	8.8	0.90647888	2.1%	8.80 [7.02, 10.58]		
SIL023	3.6	0.39019949	2.4%	3.60 [2.84, 4.36]		-
SIL025	6.8	1.2004901	1.9%	6.80 [4.45, 9.15]		
SIL027		1.54476998	1.6%	5.79 [2.76, 8.82]		
Subtotal (95% CI)			11.2%	7.44 [4.69, 10.18]		
Heterogeneity: Tau2 =	10.17: Chi ² = 55.4	43. df = 5 (P <	0.00001			
Test for overall effect:				,,		
10.2.4 Europe						
SIL13		0.68445024	2.3%	9.50 [8.16, 10.84]		
SIL36		0.71619815	2.2%	10.00 [8.60, 11.40]		
SIL37	10.85	0.66333333	2.3%	10.85 [9.55, 12.15]		
TAD015	7.3	0.49739114	2.4%	7.30 [6.33, 8.27]		-
TAD03	7.3	1.09601551	2.0%	7.30 [5.15, 9.45]		
TAD09	11.1	2.11112943	1.3%	11.10 [6.96, 15.24]		
VAR006	7.79	0.63463489	2.3%	7.79 [6.55, 9.03]		-
VAR007	10.9	0.81943603	2.2%	10.90 [9.29, 12.51]		
VAR015	4.56	4.58940225	0.4%	4.56 [-4.44, 13.56]		
Subtotal (95% CI)			17.3%	9.14 [7.98, 10.30]		•
Heterogeneity: Tau2 =	2.10: Chi ² = 35.22	2. df = 8 (P < 0)	0.0001): 1			•
Test for overall effect:	Z = 15.43 (P < 0.0					
10.2.5 North America		0.7140505	2 201	0.30/3.00 10 ==:		
SIL003		0.71435285	2.2%	9.30 [7.90, 10.70]		
SIL011		1.00020314	2.0%	8.90 [6.94, 10.86]		
SIL014		0.97966168	2.1%	9.17 [7.25, 11.09]		
SIL026	2.1	0.5999588	2.3%	2.10 [0.92, 3.28]		
SIL035a		0.56424471	2.3%	6.10 [4.99, 7.21]		_
SIL035b		0.81482317	2.2%	6.80 [5.20, 8.40]		
SIL31		0.68256437	2.3%	11.10 [9.76, 12.44]		
TAD01	8	0.79948976	2.2%	8.00 [6.43, 9.57]		
TAD07	6.9	0.75012602	2.2%	6.90 [5.43, 8.37]		
TAD08		0.60016134	2.3%	9.30 [8.12, 10.48]		
Subtotal (95% CI)			22.1%	7.74 [6.00, 9.49]		•
Heterogeneity: Tau ² = Test for overall effect:			0.00001); $I^2 = 93\%$		
10.2.6 South America	a					
		1 46262421	1 70/	11 20 (0 22 14 07)		
SIL53	11.2	1.46262421	1.7%	11.20 [8.33, 14.07]		
Subtotal (95% CI)			1.7%	11.20 [8.33, 14.07]		•
Heterogeneity: Not ap Test for overall effect:		0001)				
10.2.7 Oceania						
SIL028	6 30	1.18793939	1.9%	6.39 [4.06, 8.72]		
Subtotal (95% CI)	0.33	1.101 55555	1.9%	6.39 [4.06, 8.72]		•
Heterogeneity: Not ap	nlicable		,			_
Test for overall effect:		0001)				
restroi overali ellect:	2 - 3.30 (F < 0.00	,001)				
Total (95% CI)			100.0%	8.35 [7.69, 9.02]		•
Heterogeneity: Tau ² =	4.60: Chi ² = 555	98. df = 46 (P				<u> </u>
Test for overall effect:			. 5.5000	-,,. 32/0		5 10
Test for subgroup diff			= 0.0009	$I^2 = 73.6\%$	Favours no effect	ravours effect
Forest plot of comp					400 54	

Forest plot of comparison: 10 IIEF-EF change scores: Continent, outcome: 10.2 Effect estimate intervention groups.

Figure 14 (Analysis 11.1)

6	D://			Mean Difference	Mean Difference
Study or Subgroup 11.1.1 Singlecenter	Mean Difference	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
SIL006	6.38	0.95143	1.6%	6.38 [4.52, 8.24]	
SIL007		1.75362482	0.7%	0.30 [-3.14, 3.74]	
SIL025	1.4	1.0002526	1.5%	1.40 [-0.56, 3.36]	
SIL027		2.07735223	0.6%	0.92 [-3.15, 4.99]	
SIL1b SIL44		5.64137864 1.27043518		0.80 [-10.26, 11.86]	
VAR015		4.85004527	1.2% 0.1%	1.70 [-0.79, 4.19] 3.63 [-5.88, 13.14]	
Subtotal (95% CI)	3.03		5.8%	2.36 [0.08, 4.65]	
Heterogeneity: Tau ² =			0.003); I ²	= 70%	
Test for overall effect:	Z = 2.03 (P = 0.04)	4)			
11.1.2 Multicenter					
SIL001	2.3	0.6798897	2.1%	2.30 [0.97, 3.63]	
SIL002		0.66312884	2.2%	5.20 [3.90, 6.50]	
SIL003		0.71429868	2.1%	3.60 [2.20, 5.00]	
SIL009		1.41138514	1.0% 1.5%	4.60 [1.83, 7.37]	
SIL011 SIL014	3.4 1.86	0.9617741	1.6%	3.40 [1.44, 5.36] 1.86 [-0.03, 3.75]	
SIL016		0.89950884	1.7%	2.20 [0.44, 3.96]	
SIL017		0.59961949	2.3%	1.40 [0.22, 2.58]	
SIL018		0.59965555	2.3%	0.20 [-0.98, 1.38]	
SIL022		0.41837395	2.7%	2.10 [1.28, 2.92]	
SIL023		0.38152839	2.8%	2.20 [1.45, 2.95]	
SIL026 SIL028		0.69990606 1.24772593	2.1% 1.2%	-0.50 [-1.87, 0.87] 1.24 [-1.21, 3.69]	
SIL028		0.69971892	2.1%	1.10 [-0.27, 2.47]	
SIL034		1.06996831	1.4%	2.66 [0.56, 4.76]	
SIL035a	0.2	0.6208823	2.3%	0.20 [-1.02, 1.42]	
SIL035b		0.81363636	1.9%	-0.90 [-2.49, 0.69]	
SIL53		1.54924372	0.9%	2.50 [-0.54, 5.54]	
TAD001 TAD004	0.1	1.3618352	1.1% 1.6%	0.10 [-2.57, 2.77]	
TAD004		0.94030178 0.77158927	2.0%	2.10 [0.26, 3.94] 0.87 [-0.64, 2.38]	
TAD006		1.60067954	0.8%	2.30 [-0.84, 5.44]	
TAD007		0.95714435	1.6%	2.10 [0.22, 3.98]	
TAD008		1.07428196	1.4%	1.20 [-0.91, 3.31]	
TAD009		0.88085302	1.7%	1.30 [-0.43, 3.03]	
TAD01 TAD012		1.09985226 0.78135299	1.4% 1.9%	-0.90 [-3.06, 1.26]	
TAD012 TAD015		0.73057328	2.0%	0.49 [-1.04, 2.02] 3.30 [1.87, 4.73]	
TAD018	1.8	0.5100098	2.5%	1.80 [0.80, 2.80]	
TAD02	1.1	0.76051316	2.0%	1.10 [-0.39, 2.59]	
TAD04		0.95506746	1.6%	2.60 [0.73, 4.47]	
TAD06	0.7	0.7199074	2.1%	0.70 [-0.71, 2.11]	
TAD07 TAD08		1.08074954 0.79963012	1.4% 1.9%	-0.20 [-2.32, 1.92] 0.30 [-1.27, 1.87]	
TAD09		0.94285714	1.6%	0.40 [-1.45, 2.25]	
TAD10		0.68914269	2.1%	1.40 [0.05, 2.75]	
TAD11		0.69350381	2.1%	2.40 [1.04, 3.76]	
TAD16		0.61529978	2.3%	1.10 [-0.11, 2.31]	
TAD18		0.89924413	1.7%	1.00 [-0.76, 2.76]	
VAR005 VAR006		0.38590553 0.47433528	2.8%	2.00 [1.24, 2.76] 2.05 [1.12, 2.98]	
VAROUS VAROU7		0.47433328	1.5%	1.60 [-0.35, 3.55]	
VAR008		0.7199074	2.1%	1.69 [0.28, 3.10]	
VAR018	1.4	0.5230701	2.5%	1.40 [0.37, 2.43]	
VAR019		0.48540962	2.6%	1.40 [0.45, 2.35]	
VAR020		0.96670525	1.6%	0.48 [-1.41, 2.37]	
VAR09 VAR10		0.64250837 0.66312884	2.2%	1.60 [0.34, 2.86] 1.40 [0.10, 2.70]	
VAR10 VAR11		0.40379108	2.2%	0.50 [-0.29, 1.29]	
Subtotal (95% CI)	0.3	0.403/3100	94.2%	1.52 [1.19, 1.84]	
Heterogeneity: Tau ² =					1
Test for overall effect:	Z = 9.20 (P < 0.00)	0001)			
Total (95% CI)			100.0%	1.59 [1.25, 1.92]	
Heterogeneity: Tau ² =	0.89; Chi ² = 147.	36, df = 55 (P			
Test for overall effect:	Z = 9.31 (P < 0.00)	0001)			-10 -5 0 5 10 Favours no effect Favours effect
Test for subgroup diff	$ferences: Chi^2 = 0.5$	2, df = 1 (P =	0.47), I ²	= 0%	Tarous chet

Test for subgroup differences: Chi² = 0.52, df = 1 (P = 0.47), l² = 0%

Forest plot of comparison: 11 IIEF-EF change scores: Single-center study, outcome: 11.1 Effect estimate placebo groups.

Figure 15 (Analysis 11.2)

				Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
11.2.1 Singlecenter					
SIL006	11.08	1.49240501	1.5%	11.08 [8.15, 14.01]	
SIL007	9.3	1.75362482	1.3%	9.30 [5.86, 12.74]	
SIL025	6.8	1.2004901	1.6%	6.80 [4.45, 9.15]	
SIL027	5.79	1.54476998	1.4%	5.79 [2.76, 8.82]	
SIL1b		5.18780675	0.3%	6.00 [-4.17, 16.17]	
SIL44		2.76080863	0.9%	13.30 [7.89, 18.71]	
VAR015	4.56	4.58940225	0.4%	4.56 [-4.44, 13.56]	
Subtotal (95% CI)			7.6%	8.45 [6.30, 10.60]	•
Heterogeneity: Tau ² =			0.06); l* =	= 51%	
Test for overall effect:	Z = 7.70 (P < 0.00)	0001)			
11.2.2 Multicenter					
	0.1	0.67003366	1.00/	0.10 (7.77.10.43)	
SILOO1 SILOO2		0.67983266	1.9%	9.10 [7.77, 10.43]	
				11.70 [10.40, 13.00]	
SIL003 SIL009		0.71435285 0.90647888	1.9% 1.8%	9.30 [7.90, 10.70]	
SIL011		1.00020314	1.8%	8.80 [7.02, 10.58] 8.90 [6.94, 10.86]	
SIL011		0.97966168	1.8%	9.17 [7.25, 11.09]	
SIL016		0.89960563	1.8%	8.00 [6.24, 9.76]	
SIL017		0.59961949	2.0%	8.70 [7.52, 9.88]	_
SIL018		0.60008187	2.0%	6.10 [4.92, 7.28]	_
SIL022		0.31698117	2.1%	9.50 [8.88, 10.12]	-
SIL023		0.39019949	2.0%	3.60 [2.84, 4.36]	_
SIL026	2.1	0.5999588	2.0%	2.10 [0.92, 3.28]	_
SIL028		1.18793939	1.7%	6.39 [4.06, 8.72]	
SIL030		0.59958707	2.0%	5.40 [4.22, 6.58]	_
SIL034		0.92024897	1.8%	10.37 [8.57, 12.17]	-
SIL035a		0.51925763	2.0%	6.10 [5.08, 7.12]	_
SIL035b		0.81661203	1.9%	6.80 [5.20, 8.40]	
SIL53		1.46262421	1.5%	11.20 [8.33, 14.07]	
TAD001		0.99393222	1.8%	7.80 [5.85, 9.75]	
TAD004		0.95863335	1.8%	9.40 [7.52, 11.28]	-
TAD005	9.35	0.80414166	1.9%	9.35 [7.77, 10.93]	
TAD006	9.3	0.80016665	1.9%	9.30 [7.73, 10.87]	_
TAD007	8.5	0.70502286	1.9%	8.50 [7.12, 9.88]	_
TAD008	7	0.71851699	1.9%	7.00 [5.59, 8.41]	_
TAD009	4.5	0.90264274	1.8%	4.50 [2.73, 6.27]	-
TAD01	8	0.79948976	1.9%	8.00 [6.43, 9.57]	_
TAD012	8.03	0.44876926	2.0%	8.03 [7.15, 8.91]	_
TAD015		0.49739114	2.0%	7.30 [6.33, 8.27]	-
TAD018		0.48989996	2.0%	6.50 [5.54, 7.46]	_
TAD02		0.78868662	1.9%	6.00 [4.45, 7.55]	-
TAD04		1.13863886	1.7%	8.00 [5.77, 10.23]	
TAD06		1.01251693	1.8%	5.60 [3.62, 7.58]	_
TAD07		0.75012602	1.9%	6.90 [5.43, 8.37]	_
TADO8		0.60016134	2.0%	9.30 [8.12, 10.48]	-
TAD10		0.55882838		11.10 [10.00, 12.20]	_
TAD11		0.40808442 0.67618696	2.0%	9.80 [9.00, 10.60]	
TAD11 TAD16			1.9%	8.70 [7.37, 10.03]	
TAD16	7.8	0.50642857 1.2	2.0% 1.6%	5.30 [4.31, 6.29]	
VAR005		0.39467611	2.0%	7.80 [5.45, 10.15] 10.00 [9.23, 10.77]	_
VAR006		0.63463489	1.9%	7.79 [6.55, 9.03]	_
VAR007		0.81943603	1.9%	10.90 [9.29, 12.51]	_
VAR008		0.31544319		12.70 [12.08, 13.32]	_
VAR018		0.54702374	2.0%	8.60 [7.53, 9.67]	_
VAR019		0.62757064		8.50 [7.27, 9.73]	_
VAR020		1.39004796	1.5%	8.95 [6.23, 11.67]	
VAR09		0.65652973			
VAR10		0.67515839			
VAR11		0.50823958	2.0%	8.20 [7.20, 9.20]	
Subtotal (95% CI)			92.4%	8.11 [7.42, 8.80]	
Heterogeneity: Tau ² =	5.44; Chi ² = 733.8	88, df = 48 (P	< 0.0000	01); I ² = 93%	
Test for overall effect:	Z = 23.12 (P < 0.0)	00001)			
T-1-1 (050) CD			100 000	0.145-10.0	
Total (95% CI)		:	100.0%	8.14 [7.48, 8.79]	, l •
Heterogeneity: Tau ² =			< 0.0000)1); I [*] = 93%	-20 -10 0 10 20
Test for overall effect:			0.76\ 12	- 09/	Favours no effect Favours effect
Test for subgroup diff	erences: $Chi^* = 0.0$	9, at = 1 (P =	U.76), I	= 0%	

 $Forest\ plot\ of\ comparison:\ 11\ IIEF-EF\ change\ scores:\ Single-center\ study,\ outcome:\ 11.2\ Effect\ estimate\ intervention\ groups.$

Figure 16 (Analysis 12.1)

				Mean Difference	Mean Difference
Study or Subgroup	Mean Difference	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
12.1.1 Sildenafil					
SIL001	2.3	0.6798897	2.0%	2.30 [0.97, 3.63]	
SIL002 SIL003		0.66312884 0.71429868	2.0% 1.9%	5.20 [3.90, 6.50]	
SIL003		1.41138514	1.0%	3.60 [2.20, 5.00] 4.60 [1.83, 7.37]	
SIL011	3.4	1.0002526	1.5%	3.40 [1.44, 5.36]	
SIL014	1.86	0.9617741	1.5%	1.86 [-0.03, 3.75]	
SIL016	2.2	0.89950884	1.6%	2.20 [0.44, 3.96]	
SIL017		0.59961949	2.1%	1.40 [0.22, 2.58]	
SIL018		0.59965555	2.1%	0.20 [-0.98, 1.38]	
SIL022 SIL023		0.41837395 0.38152839	2.5% 2.5%	2.10 [1.28, 2.92] 2.20 [1.45, 2.95]	
SIL023		1.08010466	1.3%	2.60 [0.48, 4.72]	
SIL025	1.4	1.0002526	1.5%	1.40 [-0.56, 3.36]	
SIL026	-0.5	0.69990606	2.0%	-0.50 [-1.87, 0.87]	-
SIL027		2.07735223	0.5%	0.92 [-3.15, 4.99]	
SIL028		1.24772593	1.1%	1.24 [-1.21, 3.69]	
SIL030		0.69971892	2.0%	1.10 [-0.27, 2.47]	T
SIL034 SIL035a		1.06996831 0.59965555	1.4% 2.1%	2.66 [0.56, 4.76] 0.20 [-0.98, 1.38]	
SIL035b		0.69636364		-0.90 [-2.26, 0.46]	
SIL13		0.71429868	1.9%	0.10 [-1.30, 1.50]	
SIL15	0	2.18	0.5%	0.00 [-4.27, 4.27]	
SIL16		0.94725968		-1.20 [-3.06, 0.66]	
SIL31	0.2	0.6729535	2.0%	0.20 [-1.12, 1.52]	
SIL34 SIL35		0.69636364	2.0%	2.16 [0.80, 3.52]	
SIL35		0.73035234 0.61215244	1.9% 2.1%	4.56 [3.13, 5.99] 1.10 [-0.10, 2.30]	
SIL37		0.68587126	2.0%	1.53 [0.19, 2.87]	
SIL44		1.27043518	1.1%	1.70 [-0.79, 4.19]	+
SIL53	2.5	1.54924372	0.9%	2.50 [-0.54, 5.54]	+
Subtotal (95% CI)			50.5%	1.67 [1.10, 2.24]	•
Heterogeneity: Tau ² = Test for overall effect:			< 0.0000	01); I ² = 76%	
12.1.2 Tadalafil					
TAD001	0.1	1.14475367	1.3%	0.10 [-2.14, 2.34]	
TAD005	0.87	0.77158927	1.8%	0.87 [-0.64, 2.38]	+
TAD006	2.3	1.60067954	0.8%	2.30 [-0.84, 5.44]	+
TAD01		1.09985226		-0.90 [-3.06, 1.26]	
TAD012		0.78135299	1.8%	0.49 [-1.04, 2.02]	
TAD015 TAD018	1.8	0.73057328	1.9% 2.3%	3.30 [1.87, 4.73] 1.80 [0.80, 2.80]	
TAD010	1.1	1.0002526	1.5%	1.10 [-0.86, 3.06]	
TAD03		0.78327589	1.8%	0.10 [-1.44, 1.64]	-
TAD04	2.6	0.95506746	1.5%	2.60 [0.73, 4.47]	
TAD05		1.28569386		-1.30 [-3.82, 1.22]	
TAD06		0.92697107	1.6%	0.70 [-1.12, 2.52]	
TADO?		1.08074954		-0.20 [-2.32, 1.92]	
TAD08 TAD09		0.79963012 0.94285714	1.8%	0.30 [-1.27, 1.87] 0.40 [-1.45, 2.25]	
TAD10		0.68914269	2.0%	1.40 [0.05, 2.75]	
TAD11		0.69350381	2.0%	2.40 [1.04, 3.76]	
TAD16	1.1	0.61529978	2.1%	1.10 [-0.11, 2.31]	
TAD18	1	0.89924413	1.6%	1.00 [-0.76, 2.76]	+
Subtotal (95% CI)	0.40, 51;2 30.5	7 46 10 (0	31.0%	1.05 [0.56, 1.55]	•
Heterogeneity: Tau ² = Test for overall effect:			: 0.03); I*	= 41%	
12.1.3 Vardenafil					
VAR005	2	0.67182644	2.0%	2.00 [0.68, 3.32]	
VAR006	2.05	0.47433528	2.4%	2.05 [1.12, 2.98]	
VAR007		0.99406573	1.5%	1.60 [-0.35, 3.55]	
VAR008	1.69		1.9%	1.69 [0.28, 3.10]	
VAR015 VAR018	1.4	4.85004527 0.5230701	2.3%	3.63 [-5.88, 13.14] 1.40 [0.37, 2.43]	I
VAR018 VAR019		0.48540962	2.4%		
VAR020		0.96670525	1.5%		
VAR09	1.6	0.64250837	2.1%	1.60 [0.34, 2.86]	
VAR11	0.5	0.40379108	2.5%	0.50 [-0.29, 1.29]	₩.
Subtotal (95% CI)		10	18.6%	1.37 [0.99, 1.74]	◆
Heterogeneity: Tau ² = Test for overall effect:			.43); I ² =	0%	
Total (95% CI)			100.0%	1.42 [1.08, 1.75]	
Heterogeneity: Tau ² =	1.00; Chi ² = 166.	72, df = 58 (P			
Test for overall effect:					-4 -2 0 2 4 Favours no effect Favours effect
Test for subgroup diff	. a. our since ravours enect				


Forest plot of comparison: 12 IIEF-EF change scores: Type of PDE-5 inhibitor, outcome: 12.1 Effect estimate placebo groups.

Figure 17 (Analysis 12.2)

Study or Subgroup	Maan Difforance	c c	Waight	Mean Difference	Mean Difference
12.2.1 Sildenafil	Mean Difference	3E	Weight	IV, Random, 95% CI	IV, Random, 95% CI
SIL001	9.1	0.67983266	1.8%	9.10 [7.77, 10.43]	_
SIL001		0.66333333		11.70 [10.40, 13.00]	
SIL003		0.71435285	1.8%	9.30 [7.90, 10.70]	_
SIL009		0.90647888	1.7%	8.80 [7.02, 10.58]	-
SIL011		1.00020314	1.6%	8.90 [6.94, 10.86]	-
SIL014	9.17	0.97966168	1.6%	9.17 [7.25, 11.09]	
SIL016	8	0.89960563	1.7%	8.00 [6.24, 9.76]	_
SIL017		0.59961949	1.8%	8.70 [7.52, 9.88]	_
SIL018		0.60008187	1.8%	6.10 [4.92, 7.28]	-
SIL022		0.31698117	1.9%	9.50 [8.88, 10.12]	_
SIL023		0.39019949	1.9%	3.60 [2.84, 4.36]	-
SIL024		0.75046652	1.8%	7.20 [5.73, 8.67]	
SIL025 SIL026	6.8 2.1	1.2004901 0.5999588	1.5% 1.8%	6.80 [4.45, 9.15]	
SIL020		1.54476998	1.3%	2.10 [0.92, 3.28] 5.79 [2.76, 8.82]	
SIL027		1.18793939	1.5%	6.39 [4.06, 8.72]	
SIL030		0.59958707	1.8%	5.40 [4.22, 6.58]	_
SIL034		0.92024897	1.7%	10.37 [8.57, 12.17]	
SIL035a		0.60008187	1.8%	6.10 [4.92, 7.28]	-
SIL035b	6.8	0.67618696	1.8%	6.80 [5.47, 8.13]	_
SIL13	9.5	0.68445024	1.8%	9.50 [8.16, 10.84]	
SIL15		1.15828321	1.6%	7.00 [4.73, 9.27]	
SIL16		0.86081409	1.7%	8.40 [6.71, 10.09]	-
SIL31		0.68256437	1.8%	11.10 [9.76, 12.44]	_
SIL34		0.67618696	1.8%		_
SIL35		0.72081772	1.8%	10.66 [9.25, 12.07]	_
SIL36		0.71619815	1.8%	10.00 [8.60, 11.40]	
SIL37		0.66333333 2.76080863	1.8%	10.85 [9.55, 12.15] 13.30 [7.89, 18.71]	
SIL44 SIL53		1.46262421	0.8% 1.4%	11.20 [8.33, 14.07]	
Subtotal (95% CI)	11.2	1.40202421	50.7%	8.37 [7.37, 9.37]	•
Heterogeneity: Tau ² =	7.00: Chi ² = 447.9	95. df = 29 (P			•
Test for overall effect:					
12.2.2 Tadalafil					
TAD001	7.8	0.98163384	1.6%	7.80 [5.88, 9.72]	-
TAD005		0.80414166	1.7%	9.35 [7.77, 10.93]	_
TAD006	9.3	0.80016665	1.7%	9.30 [7.73, 10.87]	
TAD01	8	0.79948976	1.7%	8.00 [6.43, 9.57]	_
TAD012		0.44876926	1.9%	8.03 [7.15, 8.91]	_
TAD015		0.49739114	1.9%	7.30 [6.33, 8.27]	_
TAD018		0.48989996	1.9%	6.50 [5.54, 7.46]	-
TAD02		1.00020314	1.6%	6.00 [4.04, 7.96]	_
TADO3		1.09601551	1.6%	7.30 [5.15, 9.45]	
TAD04 TAD05		1.13863886 0.95310804	1.6% 1.7%	8.00 [5.77, 10.23] 7.70 [5.83, 9.57]	
TAD05		1.01251693	1.6%	5.60 [3.62, 7.58]	
TAD07		0.75012602	1.8%	6.90 [5.43, 8.37]	
TAD08		0.60016134	1.8%	9.30 [8.12, 10.48]	_
TAD09		0.55882838		11.10 [10.00, 12.20]	-
TAD10	9.8	0.40808442	1.9%	9.80 [9.00, 10.60]	-
TAD11	8.7	0.67618696	1.8%	8.70 [7.37, 10.03]	_
TAD16	5.3	0.50642857	1.9%	5.30 [4.31, 6.29]	_
TAD18	7.8	1.2	1.5%	7.80 [5.45, 10.15]	<u> </u>
Subtotal (95% CI)			33.0%	7.93 [7.15, 8.70]	•
Heterogeneity: Tau ² = Test for overall effect:			< 0.0000)1); I* = 84%	
12.2.3 Vardenafil					
VAR005		0.66305586	1.8%	10.00 [8.70, 11.30]	_
VAR006		0.63463489	1.8%	7.79 [6.55, 9.03]	_
VAR007		0.81943603	1.7%	10.90 [9.29, 12.51]	-
VAROUS		0.31544319 4.58940225	0.4%	12.70 [12.08, 13.32]	
VAR015 VAR018		0.54702374	1.8%	4.56 [-4.44, 13.56] 8.60 [7.53, 9.67]	
VAR018 VAR019		0.62757064	1.8%	8.50 [7.27, 9.73]	
VAR019 VAR020		1.39004796	1.4%	8.95 [6.23, 11.67]	
VAR09		0.65652973	1.8%	9.00 [7.71, 10.29]	-
VAR11		0.50823958	1.9%	8.20 [7.20, 9.20]	_
Subtotal (95% CI)	3.2		16.3%	9.32 [7.88, 10.77]	•
Heterogeneity: Tau ² =	4.48; Chi ² = 115.0	03, df = 9 (P < 0.00)	0.00001	1); $I^2 = 92\%$	
Test for overall effect:					
Total (95% CI)			100.0%	8.37 [7.73, 9.00]	•
Heterogeneity: Tau ² =			< 0.0000		10 5 1
Test for overall effect:	Z = 25.79 (P < 0.0)	00001)			-10 -5 0 5 10 Favours no effect Favours effect
Test for subgroup diff	$ferences: Chi^2 = 2.8$	4, df = 2 (P =	0.24), I ²	= 29.5%	The state of the s


Forest plot of comparison: 12 IIEF-EF change scores: Type of PDE-5 inhibitor, outcome: 12.2 Effect estimate intervention groups.

Figure 18 (Analysis 13.1)



Forest plot of comparison: 13 IIEF-EF change scores: Prior experience with the intervention, outcome: 13.1 Effect estimate placebo groups.

Figure 19 (Analysis 13.2)



Forest plot of comparison: 13 IIEF-EF change scores: Prior experience with the intervention, outcome: 13.2 Effect estimate intervention groups.

Sources of support

Internal sources

• No sources of support provided

External sources

• No sources of support provided

Feedback

Appendices